A First-in-Human Single and Multiple Ascending Dose Study of MT-251
NCT07423299
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Volunteers
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 19 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mirador Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- February 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Mirador Clinical Department · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.